World Health Organization Sounds Warning Over Acute Lack of Obesity Medications
Less than a tenth of people who could benefit from obesity jabs like Wegovy can access them, caution the WHO as it publishes its initial guidance on the medications.
Considering over a billion people worldwide currently living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidelines acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to broad availability to the jabs that can assist patients in reducing considerable weight, says the body.
Skinny Jab Shortage
Even in the present most favorable outlook, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation calls on countries and companies to expand access, by approaches like licensing agreements.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Obesity Injections Work
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, curb appetite and increase satiety so users consume fewer calories.
Patients typically see weight reduction after several weeks of starting on the weekly injections.
Research indicates patients may see weight return within a year of discontinuing the treatment, when their typical appetite resume.
To be carrying excess weight raises your risk for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity impacts individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
